220 related articles for article (PubMed ID: 30282116)
1. The contribution of respiratory microbiome analysis to a treatable traits model of care.
Taylor SL; O'Farrell HE; Simpson JL; Yang IA; Rogers GB
Respirology; 2019 Jan; 24(1):19-28. PubMed ID: 30282116
[TBL] [Abstract][Full Text] [Related]
2. Targeting respiratory microbiomes in COPD and bronchiectasis.
Mac Aogáin M; Tiew PY; Jaggi TK; Narayana JK; Singh S; Hansbro PM; Segal LN; Chotirmall SH
Expert Rev Respir Med; 2024; 18(3-4):111-125. PubMed ID: 38743428
[TBL] [Abstract][Full Text] [Related]
3. Precision medicine and treatable traits in chronic airway diseases - where do we stand?
Ulrik CS; Vijverberg S; Hanania NA; Diamant Z
Curr Opin Pulm Med; 2020 Jan; 26(1):33-39. PubMed ID: 31644440
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of sputum microbiome studies identifies airway disease-specific taxonomic and functional signatures.
Ghosh A; Saha S
J Med Microbiol; 2022 Dec; 72(12):. PubMed ID: 36748565
[No Abstract] [Full Text] [Related]
5. Treatable traits models of care.
McDonald VM; Holland AE
Respirology; 2024 Jan; 29(1):24-35. PubMed ID: 38087840
[TBL] [Abstract][Full Text] [Related]
6. The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions.
Polverino E; Dimakou K; Hurst J; Martinez-Garcia MA; Miravitlles M; Paggiaro P; Shteinberg M; Aliberti S; Chalmers JD
Eur Respir J; 2018 Sep; 52(3):. PubMed ID: 30049739
[TBL] [Abstract][Full Text] [Related]
7. [Composition of microorganism community in the airways of patients with chronic obstructive pulmonary disease].
Fedosenko SV; Ogorodova LM; Freidin MB; Saltykova IV; Kulikov ES; Deev IA; Kirillova NA; Selivanova PA; Balasheva II
Klin Med (Mosk); 2014; 92(8):26-32. PubMed ID: 25790693
[TBL] [Abstract][Full Text] [Related]
8. Microbiota abnormalities in inflammatory airway diseases - Potential for therapy.
Gollwitzer ES; Marsland BJ
Pharmacol Ther; 2014 Jan; 141(1):32-9. PubMed ID: 23969226
[TBL] [Abstract][Full Text] [Related]
9. The treatable traits approach to adults with obstructive airways disease in primary and secondary care.
Thomas M; Beasley R
Respirology; 2023 Dec; 28(12):1101-1116. PubMed ID: 37877554
[TBL] [Abstract][Full Text] [Related]
10. Treatable traits of chronic airways disease.
Fingleton J; Hardy J; Beasley R
Curr Opin Pulm Med; 2018 Jan; 24(1):24-31. PubMed ID: 29049049
[TBL] [Abstract][Full Text] [Related]
11. Chronic obstructive pulmonary disease and infection. Disruption of the microbiome?
Sethi S
Ann Am Thorac Soc; 2014 Jan; 11 Suppl 1():S43-7. PubMed ID: 24437405
[TBL] [Abstract][Full Text] [Related]
12. Relationship between the respiratory microbiome and the severity of airflow limitation, history of exacerbations and circulating eosinophils in COPD patients.
Millares L; Pascual S; Montón C; García-Núñez M; Lalmolda C; Faner R; Casadevall C; Setó L; Capilla S; Moreno A; Castro-Acosta AA; Alvarez-Martinez CJ; Sibila O; Peces-Barba G; Cosio BG; Agustí A; Gea J; Monsó E
BMC Pulm Med; 2019 Jun; 19(1):112. PubMed ID: 31234826
[TBL] [Abstract][Full Text] [Related]
13. The airway microbiome in COPD, bronchiectasis and bronchiectasis-COPD overlap.
Tiew PY; Jaggi TK; Chan LLY; Chotirmall SH
Clin Respir J; 2021 Feb; 15(2):123-133. PubMed ID: 33063421
[TBL] [Abstract][Full Text] [Related]
14. The lung microbiome and exacerbations of COPD.
Dy R; Sethi S
Curr Opin Pulm Med; 2016 May; 22(3):196-202. PubMed ID: 26964078
[TBL] [Abstract][Full Text] [Related]
15. Oral-lung microbiome interactions in lung diseases.
Mammen MJ; Scannapieco FA; Sethi S
Periodontol 2000; 2020 Jun; 83(1):234-241. PubMed ID: 32385873
[TBL] [Abstract][Full Text] [Related]
16. Functional effects of the microbiota in chronic respiratory disease.
Budden KF; Shukla SD; Rehman SF; Bowerman KL; Keely S; Hugenholtz P; Armstrong-James DPH; Adcock IM; Chotirmall SH; Chung KF; Hansbro PM
Lancet Respir Med; 2019 Oct; 7(10):907-920. PubMed ID: 30975495
[TBL] [Abstract][Full Text] [Related]
17. [The lung microbiome in 2015: a window on chronic lung diseases].
Andréjak C; Delhaes L
Med Sci (Paris); 2015 Nov; 31(11):971-8. PubMed ID: 26576604
[TBL] [Abstract][Full Text] [Related]
18. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial.
Rogers GB; Bruce KD; Martin ML; Burr LD; Serisier DJ
Lancet Respir Med; 2014 Dec; 2(12):988-96. PubMed ID: 25458200
[TBL] [Abstract][Full Text] [Related]
19. The Lung Microbiome and Airway Disease.
Lynch SV
Ann Am Thorac Soc; 2016 Dec; 13 Suppl 2(Suppl 5):S462-S465. PubMed ID: 28005424
[TBL] [Abstract][Full Text] [Related]
20. Moving towards a Treatable Traits model of care for the management of obstructive airways diseases.
Agusti A; Barnes N; Cruz AA; Gibson PG; Heaney LG; Inoue H; Leather D; Martinez FJ; McDonald VM; Oppenheimer J; Papi A; Pavord ID; Thomas M; Walker S; Yates L
Respir Med; 2021 Oct; 187():106572. PubMed ID: 34478992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
